<div class="flex flex-col text-sm @w-xl/main:pt-header-height pb-25">
<article class="text-token-text-primary w-full focus:outline-none [--shadow-height:45px] has-data-writing-block:pointer-events-none has-data-writing-block:-mt-(--shadow-height) has-data-writing-block:pt-(--shadow-height) [&amp;:has([data-writing-block])&gt;*]:pointer-events-auto scroll-mt-[calc(var(--header-height)+min(200px,max(70px,20svh)))]" dir="auto" tabindex="-1" data-turn-id="request-WEB:4494318f-a359-43f2-bd9a-9309ea1deefb-12" data-testid="conversation-turn-26" data-scroll-anchor="true" data-turn="assistant">
<div class="text-base my-auto mx-auto pb-10 [--thread-content-margin:--spacing(4)] @w-sm/main:[--thread-content-margin:--spacing(6)] @w-lg/main:[--thread-content-margin:--spacing(16)] px-(--thread-content-margin)">
<div class="[--thread-content-max-width:40rem] @w-lg/main:[--thread-content-max-width:48rem] mx-auto max-w-(--thread-content-max-width) flex-1 group/turn-messages focus-visible:outline-hidden relative flex w-full min-w-0 flex-col agent-turn" tabindex="-1">
<div class="flex max-w-full flex-col grow">
<div class="min-h-8 text-message relative flex w-full flex-col items-end gap-2 text-start break-words whitespace-normal [.text-message+&amp;]:mt-1" dir="auto" data-message-author-role="assistant" data-message-id="8733d22a-3c11-4806-a42b-7c45b02eb6bd" data-message-model-slug="gpt-5-1">
<div class="flex w-full flex-col gap-1 empty:hidden first:pt-[1px]">
<div class="markdown prose dark:prose-invert w-full break-words light markdown-new-styling">
<p data-start="81" data-end="441"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Novo Nordisk has officially launched Ozempic in India, pricing the 0.25 mg weekly dose at ₹2,200, marking a significant entry into the country&rsquo;s rapidly growing diabetes and obesity care market. While the drug is already a global bestseller, experts caution that it is not a quick-fix solution and must be paired with disciplined lifestyle changes.</span></p>
<p data-start="443" data-end="1015"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Strict regime essential, say doctors</span><br data-start="483" data-end="486"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Health experts highlight that Ozempic, used for both type 2 diabetes management and weight control, requires patients to follow a structured regimen.</span><br data-start="639" data-end="642"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">&ldquo;It is a medicine used for both diabetes and weight treatment. While undergoing the course, one should follow a strict regime and engage in regular exercise,&rdquo; said Dr. Unnikrishnan of Chellaram Diabetes Institute.</span><br data-start="859" data-end="862"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">He added that the drug supports broader health improvements, including reducing risks related to heart and kidney complications in diabetes patients.</span></p>
<p data-start="1017" data-end="1304"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">India becomes a key market</span><br data-start="1047" data-end="1050"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">India&rsquo;s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), approved Ozempic (semaglutide) in October this year for adult patients with type 2 diabetes. The injectable will be available in 0.25 mg, 0.5 mg, and 1 mg strengths.</span></p>
<p data-start="1306" data-end="1602"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">With India holding the world&rsquo;s second-largest type 2 diabetes population and rapidly rising obesity numbers, the country has become a significant market for metabolic and weight-loss medications. Analysts estimate the global segment could reach $150 billion annually by the end of the decade.</span></p>
<p data-start="1604" data-end="1955"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Global bestseller with multiple benefits</span><br data-start="1648" data-end="1651"><span style="font-family: georgia, palatino, serif; font-size: 12pt;">Ozempic, first approved in the U.S. in 2017, has grown popular worldwide, including for off-label weight-loss use. Novo Nordisk states that beyond glycemic control, the drug can help reduce cardiovascular risks, protect kidney function, and support weight loss of up to 8 kg in diabetes patients.</span></p>
<p data-start="1957" data-end="2145" data-is-last-node="" data-is-only-node=""><span style="font-family: georgia, palatino, serif; font-size: 12pt;">In India, the medication will be available only on prescription from endocrinologists or internal medicine specialists, and is not approved for cosmetic or non-medical weight loss.</span></p>
</div>
</div>
</div>
</div>
<div class="z-0 flex min-h-[46px] justify-start">&nbsp;</div>
<div class="mt-3 w-full empty:hidden">
<div class="text-center">&nbsp;</div>
</div>
</div>
</div>
</article>
</div>
<div class="pointer-events-none h-px w-px absolute bottom-0" aria-hidden="true" data-edge="true">&nbsp;</div>

n India at ₹2,200 for the 0.25 mg weekly dose, tapping into the country’s fast-growing diabetes and obesity market. The drug, however, is not a quick fix.  A box of Ozempic made by Novo Nordisk is seen at a pharmacy

Doctors urge strict routine as Ozempic debuts in India for diabetes and weight management

Doctors Caution as Ozempic Debuts in India

Doctors urge strict routine as Ozempic debuts in India for diabetes and weight management

December 12, 2025 | 22:35 IST